In a watershed moment for federal healthcare policy, the Centers for Medicare & Medicaid Services (CMS) has officially activated the Medicare GLP-1 Bridge Program. Launching in July 2026, this provisional demonstration circumvents longstanding statutory exclusions to provide eligible beneficiaries with unprecedented access to specific weight-loss medications.

The Policy paradigm Shift

Under traditional federal law, Medicare Part D plans are strictly prohibited from covering medications prescribed explicitly for weight loss. However, leveraging the Center for Medicare and Medicaid Innovation (CMMI) demonstration authority, CMS has engineered a ingenious workaround. This centralized system handles approvals, processes claims, and pays pharmacies directly, entirely bypassing the traditional Part D plan infrastructure and its inherent coverage limitations.

Eligibility and comprehended Medications

The program specifically covers three FDA-approved GLP-1 medications: Wegovy (injections and tablets), Zepbound (KwikPen), and Foundayo. To qualify, beneficiaries must be enrolled in Medicare with prescription drug coverage and meet stringent clinical criteria. This includes a Body Mass Index (BMI) of 35 or higher, a BMI of 30 or higher with comorbidities like heart failure or chronic kidney disease, or a BMI of 27 or higher with other significant health risks such as pre-diabetes or a history of heart attack.

Financial implications

Participants in the Bridge Program will pay a fixed, predictable $50 monthly copayment. Crucially, because this is a separate demonstration model, this $50 copay does not count toward the beneficiary’s Part D deductible or annual out-of-pocket limit. Furthermore, traditional cost-assistance programs like Extra Help cannot be applied to this specific copayment, a noteworthy caveat that policy advocates are actively monitoring for potential disparate impacts on low-income seniors.

Official Social Media Communique

View this post on Instagram

A post shared by Medicare Rights Center (@medicarerights)